Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.96 |
| ▸ | HPGD | P15428 | 7/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.96 |
| ▸ | CA9 | Q16790 | 7/20 | 0.96 |
| ▸ | GAA | P10253 | 6/20 | 0.96 |
| ▸ | GLA | P06280 | 5/20 | 0.96 |
| ▸ | CA12 | O43570 | 5/20 | 0.96 |
| ▸ | CA1 | P00915 | 5/20 | 0.96 |
| ▸ | CASP1 | P29466 | 4/20 | 0.96 |
| ▸ | CASP7 | P55210 | 4/20 | 0.96 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.62 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37677 | 0.98 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| SCHEMBL29645144 | 0.98 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| SCHEMBL28806970 | 0.98 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| Bromide SCHEMBL30457821 | 0.96 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| Hydrochloric Acid SCHEMBL2545954 | 0.96 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| Hydrochloric Acid SCHEMBL30762676 | 0.96 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| Bromide SCHEMBL18007249 | 0.96 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| Hydrochloric Acid SCHEMBL567469 | 0.96 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| Bromide SCHEMBL28878217 | 0.95 | ALDH1A1 (0.93) | ALDH1A1KDM4EHPGDHSD17B10CA9 | |
| Acetic Acid SCHEMBL3998167 | 0.90 | ALDH1A1 (0.84) | ALDH1A1KDM4EHPGDHSD17B10CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201624-A1 | NON-INVASIVE ENERGY UPCONVERSION METHODS AND SYSTEMS FOR IN-SITU PHOTOBIOMODULATION | IMMUNOLIGHT, LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230029054-A1 | NON-INVASIVE SYSTEMS AND METHODS FOR IN-SITU PHOTOBIOMODULATION | IMMUNOLIGHT, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| US-11383098-B2 | Non-invasive energy upconversion methods and systems for in-situ photobiomodulation | IMMUNOLIGHT, LLC (US) | 2022-07-12 | — | — | US | disclosed |
| US-11324965-B2 | Non-invasive energy upconversion methods and systems | IMMUNOLOIGHT, LLC. (US) | 2022-05-10 | — | — | US | disclosed |
| CN-113274496-A | Non-invasive system and method for in situ photobiomodulation | 免疫之光有限责任公司 | 2021-08-20 | — | — | CN | disclosed |
| US-10835756-B2 | Advanced methods and systems for treating cell proliferation disorders | IMMUNOLIGHT, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200078600-A1 | NON-INVASIVE ENERGY UPCONVERSION METHODS AND SYSTEMS FOR IN-SITU PHOTOBIOMODULATION | IMMUNOLIGHT, LLC. (US) | 2020-03-12 | — | — | US | disclosed |
| US-10493296-B2 | Non-invasive energy upconversion methods and systems for in-situ photobiomodulation | IMMUNOLIGHT, LLC (US) | 2019-12-03 | — | — | US | disclosed |
| US-20190336785-A1 | NON-INVASIVE ENERGY UPCONVERSION METHODS AND SYSTEMS | IMMUNOLIGHT, LLC (US) | 2019-11-07 | — | — | US | disclosed |
| US-20190336786-A1 | NON-INVASIVE SYSTEMS AND METHODS FOR IN-SITU PHOTOBIOMODULATION | IMMUNOLIGHT, LLC. (US) | 2019-11-07 | — | — | US | disclosed |
| US-20110263920-A1 | ADVANCED METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS | DUKE UNIVERSITY (US) | 2011-10-27 | — | — | US | disclosed |
| CN-102056625-A | Non-invasive system and method for in situ photobiomodulation | IMMUNOLIGHT LLC | 2011-05-11 | — | — | CN | disclosed |
| US-20110021970-A1 | NON-INVASIVE ENERGY UPCONVERSION METHODS AND SYSTEMS FOR IN-SITU PHOTOBIOMODULATION | DUKE UNIVERSITY (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2268311-A1 | NON-INVASIVE SYSTEMS AND METHODS FOR IN-SITU PHOTOBIOMODULATION | Immunolight, Llc. (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20100016783-A1 | NON-INVASIVE SYSTEMS AND METHODS FOR IN-SITU PHOTOBIOMODULATION | DUKE UNIVERSITY (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2010009106-A1 | ADVANCED METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS | BOURKE FREDERIC A JR (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20100003316-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS USING PLASMONICS ENHANCED PHOTOSPECTRAL THERAPY (PEPST) AND EXCITON-PLASMON ENHANCED PHOTOTHERAPY (EPEP) | DUKE UNIVERSITY (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2009105662-A9 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS USING PLASMONICS ENHANCED PHOTOSPECTRAL THERAPY (PEPST) AND EXCITON-PLASMON ENHANCED PHOTOTHERAPY (EPEP) | IMMUNOLIGHT, LLC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009124189-A1 | NON-INVASIVE SYSTEMS AND METHODS FOR IN-SITU PHOTOBIOMODULATION | IMMUNOLIGHT, LLC (US) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009105662-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS USING PLASMONICS ENHANCED PHOTOSPECTRAL THERAPY (PEPST) AND EXCITON-PLASMON ENHANCED PHOTOTHERAPY (EPEP) | IMMUNOLIGHT, LLC. (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336785-A1 | NON-INVASIVE ENERGY UPCONVERSION METHODS AND SYSTEMS | FURIN, NFATC1, HAVCR2 | ALDH1A1 3124/4885KDM4E 4709/4885HPGD 2974/4885 |
| US-10835756-B2 | Advanced methods and systems for treating cell proliferation disorders | MKI67, TMPRSS15, KIT | ALDH1A1 4643/4885KDM4E 2360/4885HPGD 1825/4885 |
| US-10493296-B2 | Non-invasive energy upconversion methods and systems for in-situ photobiomodulation | MAVS, NLN, FURIN | ALDH1A1 3589/4885KDM4E 4490/4885HPGD 3470/4885 |
| US-20230201624-A1 | NON-INVASIVE ENERGY UPCONVERSION METHODS AND SYSTEMS FOR IN-SITU PHOTOBIOMODULATION | MAVS, NLN, FURIN | ALDH1A1 3589/4885KDM4E 4490/4885HPGD 3470/4885 |
| US-11383098-B2 | Non-invasive energy upconversion methods and systems for in-situ photobiomodulation | MAVS, NLN, FURIN | ALDH1A1 3589/4885KDM4E 4490/4885HPGD 3470/4885 |
| US-20110021970-A1 | NON-INVASIVE ENERGY UPCONVERSION METHODS AND SYSTEMS FOR IN-SITU PHOTOBIOMODULATION | MAVS, NLN, FURIN | ALDH1A1 3589/4885KDM4E 4490/4885HPGD 3470/4885 |
| US-20200078600-A1 | NON-INVASIVE ENERGY UPCONVERSION METHODS AND SYSTEMS FOR IN-SITU PHOTOBIOMODULATION | MAVS, NLN, FURIN | ALDH1A1 3589/4885KDM4E 4490/4885HPGD 3470/4885 |
| US-20110263920-A1 | ADVANCED METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS | MKI67, TMPRSS15, NPEPPS | ALDH1A1 3041/4885KDM4E 3443/4885HPGD 884/4885 |
| US-11324965-B2 | Non-invasive energy upconversion methods and systems | FURIN, NFATC1, HAVCR2 | ALDH1A1 3124/4885KDM4E 4709/4885HPGD 2974/4885 |
| US-20100003316-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS USING PLASMONICS ENHANCED PHOTOSPECTRAL THERAPY (PEPST) AND EXCITON-PLASMON ENHANCED PHOTOTHERAPY (EPEP) | MKI67, NPEPPS, TMPRSS15 | ALDH1A1 3623/4885KDM4E 3712/4885HPGD 1645/4885 |
| US-20190336786-A1 | NON-INVASIVE SYSTEMS AND METHODS FOR IN-SITU PHOTOBIOMODULATION | MAVS, NFATC1, HAVCR2 | ALDH1A1 4381/4885KDM4E 4429/4885HPGD 2289/4885 |
| US-20100016783-A1 | NON-INVASIVE SYSTEMS AND METHODS FOR IN-SITU PHOTOBIOMODULATION | MAVS, NFATC1, HAVCR2 | ALDH1A1 4381/4885KDM4E 4429/4885HPGD 2289/4885 |
| US-20230029054-A1 | NON-INVASIVE SYSTEMS AND METHODS FOR IN-SITU PHOTOBIOMODULATION | MAVS, NFATC1, HAVCR2 | ALDH1A1 4381/4885KDM4E 4429/4885HPGD 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.